摘要
目的观察应用细胞因子诱导的杀伤细胞（CIK）回输治疗对膀胱癌术后患者CD4、CD8细胞水平的影响，探讨CIK预防膀胱癌术后局部复发的疗效及安全性。方法对34例膀胱癌术后患者行CIK回输治疗，监测膀胱肿瘤复发情况、治疗前、治疗1月及治疗1年后的CD4、CD8、CD4／CD8水平、血白细胞、血肌酐、谷丙转氨酶、谷草转氨酶等指标。结果随访24～36个月，仅1例PT1G3患者肿瘤复发（2．94％），时间为术后第24个月。治疗前CD4、CD8、CD4／CD8分别为25．3±4．1、27．5±3．9、0．92±0．17，治疗1月后和1年后cD4、CD8、CD4／CD8分别为36．3±5．1、22．8±2．6、1．59±0．28和35．6±3．8、21．9±3．1、1．62±0．34，治疗前后CD4、CD8水平差异有显著性（P〈0．05）。治疗前后血白细胞、血肌酐、谷丙转氨酶、谷草转氨酶等指标差异无显著性（P〉0．05）。结论CIK细胞回输免疫治疗预防膀胱癌术后局部复发安全有效。
Objective To observe the effect of CD4 and CD8 cell levels on cytokine induced killer ceils （CIK） cell transfusion therapy in the post-operation patients with bladder cancer and explore the efficacy and safety of CIK infusion to prevent local recurrence of bladder cancer post-operation. Methods 34 patients with bladder cancer after TURBT or partial cystectomy received CIK infusion. CD4, CD8, CD4/CD8, creatinine, ALT, and AST were observed. Results All these patients were followed up for 24 to 36 months. Recurrence was detected in one patient in the 24^th month after operation. The values of CD4, CD8, CD4/CD8 of these patients pre-operation were 25.3±4.1, 27.5±3.9, 0.92±0.17, respectively, but were 36.3±5.1, 22.8±2.6, 1.59±0.28 1 month after operation and 35.6± 3.8, 21.9± 3.1, 1.62±0.34 one year after operation. CIK significantly improved immunizing ability in these patients （P〈0.05）. No systemic side effect was observed in hematopoietic system, or in renal and liver function （P〉0.05）. Conclusion The immunizing therapy of cytokine induced killer cells infusion to prevent local recurrence of bladder cancer post-operation is effective and safe.
出处
《现代泌尿外科杂志》
CAS
2009年第3期215-217,共3页
Journal of Modern Urology
基金
中山市卫生局研究基金(No.B200564)
关键词
膀胱肿瘤
复发
CIK细胞
免疫治疗
bladder neoplasms
recurrence
cytokine induced killer cell
immunizing therapy
